Israel - inglês - Ministry of Health

teva israel ltd - tranexamic acid - solution for injection - tranexamic acid 500 mg / 5 ml - tranexamic acid - tranexamic acid - prevention and treatment of haemorrhages due to general or local fibrinolysis in adults and children from one year.specific indications include:- haemorrhage caused by general or local fibrinolysis such as: * menorrhagia and metrorrhagia * gastrointestinal bleeding * haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract- ear nose throat surgery (adenoidectomy, tonsillectomy, dental extractions)- gynaecological surgery or disorders of obstetric origin- thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery- management of haemorrhage due to the administration of a fibrinolytic agent.

Cingapura - inglês - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - vedolizumab - injection, solution - vedolizumab 108mg/0.68ml

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoprolol tartrate, quantity: 5 mg - injection - excipient ingredients: water for injections; sodium chloride - - intravenous therapy: disturbances of cardiac rhythm, in particular supraventricular tachyarrhythmias.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - theophylline hydrate 20.63 mg/ml (as 25mg/ml of aminophylline) - solution for injection - 250 mg/10ml - active: theophylline hydrate 20.63 mg/ml (as 25mg/ml of aminophylline) excipient: edamine as 25mg/ml of aminophylline + extra q.s. to adjust ph (limit nmt 295 mg / g of theophylline) water for injection - dbl™aminophylline injection is indicated for the treatment of reversible bronchospasm associated with chronic bronchitis, emphysema, bronchial asthma and chronic obstructive pulmonary disease. it may also be used for paroxysmal dyspnoea associated with left heart failure

Estados Unidos - inglês - NLM (National Library of Medicine)

seroyal usa - rumex crispus root (unii: 9n1rm2s62c) (rumex crispus root - unii:9n1rm2s62c) - rumex crispus root 1 [hp_x] - indications for the temporary relief of coughs and gastric discomforts indications for the temporary relief of coughs and gastric discomforts directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

ebos group ltd - allergen extracts 0.1 ic/ml (rumex acetosa pollen extract); allergen extracts 1 ic/ml (rumex acetosa pollen extract); allergen extracts 10 ic/ml (rumex acetosa pollen extract) - solution for injection - active: allergen extracts 0.1 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 1 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water active: allergen extracts 10 ic/ml (rumex acetosa pollen extract) excipient: aluminium hydroxide gel mannitol phenol sodium chloride water

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.